Valence8 Us LP Apellis Pharmaceuticals, Inc. Transaction History
Valence8 Us LP
- $213 Billion
- Q1 2025
A detailed history of Valence8 Us LP transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Valence8 Us LP holds 13,100 shares of APLS stock, worth $256,629. This represents 0.16% of its overall portfolio holdings.
Number of Shares
13,100Holding current value
$256,629% of portfolio
0.16%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding APLS
# of Institutions
287Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$241 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$239 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$233 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$198 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$189 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.15B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...